Article Details
Retrieved on: 2021-04-27 12:33:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel ...
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here